Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
45
FTRE Quote, Financials, Valuation and Earnings
Last price:
$4.96
Seasonality move
:
-18.14%
Day range:
$4.88 - $5.08
52-week range:
$3.97 - $28.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.16x
P/B ratio:
0.52x
Volume:
1.7M
Avg. volume:
2.6M
1-year change:
-81.65%
Market cap:
$443.5M
Revenue:
$2.7B
EPS (TTM):
-$8.79
Analysts' Opinion
-
Consensus RatingFortrea Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.66, Fortrea Holdings has an estimated upside of 35.9% from its current price of $4.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.75 representing 100% downside risk from its current price of $4.95.
Fair Value
-
According to the consensus of 10 analysts, Fortrea Holdings has 35.9% upside to fair value with a price target of $6.66 per share.
FTRE vs. S&P 500
-
Over the past 5 trading days, Fortrea Holdings has underperformed the S&P 500 by -2.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fortrea Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fortrea Holdings revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Fortrea Holdings reported revenues of $651.3M.
Earnings Growth
-
Fortrea Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Fortrea Holdings reported earnings per share of -$6.25.
Enterprise value:
1.6B
EV / Invested capital:
--
Price / LTM sales:
0.16x
EV / EBIT:
240.84x
EV / Revenue:
0.58x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
10.72x
Price / Operating cash flow:
3.03x
Enterprise value / EBITDA:
224.17x
Gross Profit (TTM):
$542.8M
Return On Assets:
-21.75%
Net Income Margin (TTM):
-29.43%
Return On Equity:
-58.22%
Return On Invested Capital:
-30.43%
Operating Margin:
-3.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.8B | $2.7B | $662.1M | $651.3M | |
| Gross Profit | $736.3M | $546.1M | $542.8M | $107.9M | $116.5M | |
| Operating Income | $195.2M | $4.4M | -$102.5M | -$34.1M | -$24.8M | |
| EBITDA | $257.5M | $86.8M | -$552.6M | -$17.9M | -$506.2M | |
| Diluted EPS | $1.88 | -$1.35 | -$8.79 | -$1.13 | -$6.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $1.2B | $1.2B | $970.3M | |
| Total Assets | -- | -- | $4.3B | $4.2B | $3.1B | |
| Current Liabilities | -- | -- | $656.5M | $818.3M | $999.1M | |
| Total Liabilities | -- | -- | $2.5B | $2.6B | $2.3B | |
| Total Equity | -- | -- | $1.8B | $1.6B | $858.8M | |
| Total Debt | -- | -- | $1.6B | $1.6B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $141.3M | $144.8M | $164.2M | -$25.6M | -$124.2M | |
| Cash From Investing | -$59.1M | -$24.8M | $276.9M | -$9.2M | $16.1M | |
| Cash From Financing | -$64.2M | -$144M | -$430.7M | $21.3M | $88.4M | |
| Free Cash Flow | $82.1M | $111.4M | $145.1M | -$34.9M | -$127.1M | |
FTRE
Sector
Market Cap
$443.5M
$34.4M
Price % of 52-Week High
17.33%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-82.45%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.97
200-day SMA
Sell
Level
$12.71
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$5.07
Relative Strength Index (RSI14)
Sell
Level
47.51
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-57.2549
50-day SMA
Sell
Level
$5.03
MACD (12, 26)
Buy
Level
1.37
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.911)
Sell
CA Score
(Annual)
Level (-0.8803)
Buy
Beneish M-Score
(Annual)
Level (-3.8093)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (0.8114)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Stock Forecast FAQ
In the current month, FTRE has received 1 Buy ratings 9 Hold ratings, and 0 Sell ratings. The FTRE average analyst price target in the past 3 months is $6.66.
-
Where Will Fortrea Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fortrea Holdings share price will rise to $6.66 per share over the next 12 months.
-
What Do Analysts Say About Fortrea Holdings?
Analysts are divided on their view about Fortrea Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fortrea Holdings is a Sell and believe this share price will drop from its current level to $4.75.
-
What Is Fortrea Holdings's Price Target?
The price target for Fortrea Holdings over the next 1-year time period is forecast to be $6.66 according to 10 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is FTRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fortrea Holdings is a Hold. 9 of 10 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FTRE?
You can purchase shares of Fortrea Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fortrea Holdings shares.
-
What Is The Fortrea Holdings Share Price Today?
Fortrea Holdings was last trading at $4.96 per share. This represents the most recent stock quote for Fortrea Holdings. Yesterday, Fortrea Holdings closed at $4.95 per share.
-
How To Buy Fortrea Holdings Stock Online?
In order to purchase Fortrea Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
93
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
